Medina v. Clovis Oncology, Inc., 215 F. Supp. 3d 1094

Background

Plaintiffs (consolidated lead plaintiffs including M.Arkin (1999) LTD, Arkin Communications LTD, and City of St. Petersburg Employees’ Retirement System) sued Clovis Oncology and several executives and third parties alleging securities fraud and related Securities Act claims arising from public statements about rociletinib (an experimental lung‑cancer drug).
Core allegation: Clovis publicly reported high objective response rates (ORRs) during 2014–2015 that were allegedly based on unconfirmed tumor responses, whereas confirmatory scans (per the TIGER‑X protocol and RECIST v1.1) showed materially lower confirmed ORRs; later disclosures revealed much lower confirmed ORRs and significant safety issues (QT prolongation), triggering steep stock declines.
Procedural posture: Consolidated complaint filed; motions to dismiss by (a) Clovis and Executive Defendants, (b) Venture Capital Defendants, and (c) Underwriter Defendants. Court granted most judicial notice requests but denied notice of one unpublished abstract.
Key disputed legal questions: whether disclosures were false or misleading under Section 10(b) / Rule 10b‑5 and Securities Act Sections 11/12/15; whether plaintiffs pled scienter with particularity under the PSLRA; and whether certain defendants (Venture Capitalists, Underwriters, Ivers‑Read) can be held liable.
Trial‑protocol and regulatory law (RECIST v1.1, TIGER‑X protocol, FDA guidance on accelerated approval) are central to whether interim ORRs were required to be ‘‘confirmed’’ and whether omission of confirmatory data was misleading.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Were public ORR statements false/misleading because based on unconfirmed responses?	Plaintiffs: TIGER‑X and RECIST required confirmatory scans; Clovis reported blended/unconfirmed ORRs as if confirmed, misleading investors.	Clovis: RECIST did not necessarily require confirmation for ongoing trials; interim labels ("preliminary", "immature") made statements non‑misleading.	Court: Plaintiffs plausibly alleged misleading statements; RECIST/TIGER‑X reasonably read to require confirmation within weeks, so dismissal denied on this ground.
Did defendants have scienter (intent or recklessness) for §10(b)?	Plaintiffs: unblinded trial data available to executives; confirmed ORRs allegedly much lower; Clovis financially dependent on funding — motive and access support strong inference of scienter.	Clovis: reasonable belief in trial design and regulatory acceptance; general motive insufficient; competing inference of good‑faith belief is plausible.	Court: Considering all allegations collectively, plaintiffs pleaded a strong inference of scienter as at least as compelling as opposing inferences.
Are statements about safety and "well‑tolerated" actionable?	Plaintiffs: safety data (QT prolongation, dose interruptions, discontinuations) contradicted positive safety characterizations.	Clovis: some safety concerns were disclosed; general characterizations are opinions/optimism and not objectively verifiable.	Court: Safety statements may be objectively verifiable; pleaded facts permit claims to proceed (close call on grade‑3 QT data).
Are Venture Capital and Underwriter defendants liable (control / seller status)?	Plaintiffs: VCs exerted control via board representation and share stakes; Underwriters participated in July 2015 offering.	VCs: minority stakes and single board seats do not plead control under Section 15; Underwriters: complaint fails to allege direct buyer‑seller privity for §12(a)(2).	Court: Venture Capital defendants dismissed with prejudice (no control pled). Underwriters: §11 claims largely survive except for immaterial puffery; §12(a)(2) dismissed without prejudice — plaintiffs allowed 14 days to amend.

Key Cases Cited

Bell Atl. Corp. v. Twombly, 550 U.S. 544 (U.S. 2007) (plausibility pleading standard under Rule 8)
Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (U.S. 2007) (scienter must be shown by facts giving rise to a strong inference; compare competing inferences)
Adams v. Kinder‑Morgan, Inc., 340 F.3d 1083 (10th Cir. 2003) (framework for evaluating whether alleged statements were misleading under §10(b))
In re Level 3 Commc’ns, Inc. Sec. Litig., 667 F.3d 1331 (10th Cir. 2012) (PSLRA applies to §10(b) claims; heightened pleading for falsity and scienter)
Pinter v. Dahl, 486 U.S. 622 (U.S. 1988) (Section 12(a) requires a buyer‑seller relationship — privity‑like requirement)
Ernst & Ernst v. Hochfelder, 425 U.S. 185 (U.S. 1976) (§10(b) scienter requires intent to deceive, manipulate, or defraud)
City of Philadelphia v. Fleming Cos., Inc., 264 F.3d 1245 (10th Cir. 2001) (scienter includes recklessness; analyses of nondisclosure claims)
Anixter v. Home‑Stake Prod. Co., 77 F.3d 1215 (10th Cir. 1996) (definition of recklessness in securities context)